Skip to content

A randomized, double-blind, placebo-controlled study on the efficacy of Swiss lactobacillus in patients with refractory hypertension

A randomized, double-blind, placebo-controlled study on the efficacy of Swiss lactobacillus in patients with refractory hypertension

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400091820
Enrollment
Unknown
Registered
2024-11-04
Start date
2024-11-04
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

Lactobacillus group:12 week probiotic lactobacillus intervention
placebo group :12 week placebo-controlled intervention

Sponsors

the First Affiliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Age range: 18-75 years old (2) Meets the diagnostic criteria for refractory hypertension (taking three different types of antihypertensive drugs for more than 4 weeks, with each drug being the maximum dose or the patient's maximum tolerated dose, clinic blood pressure = 140/90mmHg, 24-hour average dynamic blood pressure = 130/80mmHg, or home blood pressure average = 135/85mmHg, or requiring the use of four antihypertensive drugs to meet the criteria, diagnosed as refractory hypertension)

Exclusion criteria

Exclusion criteria: (1) Pseudo refractory hypertension. (2) Merge serious diseases such as cardiovascular and cerebrovascular diseases, malnutrition, and thyroid diseases. (3) Combined with gastrointestinal diseases such as ulcerative colitis. (4) Have taken antibiotics or probiotic preparations in the past month (5) History of major gastrointestinal surgeries (such as subtotal gastrectomy) within the past five years (6) Complicated with infectious diseases, with obvious abnormalities in blood routine, procalcitonin and C-reactive protein

Design outcomes

Primary

MeasureTime frame
blood pressure;

Secondary

MeasureTime frame
Fecal metagenomic testing;Plasma metabolomics testing;

Countries

China

Contacts

Public ContactYue Li

the First Affiliated Hospital of Harbin Medical University

ly99ly@vip.163.com+86 139 4505 7313

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026